Search This Blog

Saturday, September 10, 2022

GeoVax to Update on Phase 2 Trials for COVID-19 Vaccine, Phase 1/2 Trial for Head and Neck Cancer

 GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 2:30 p.m. Eastern Standard Time.

A webcast of the presentation will be available at the following link: https://journey.ct.events/view/883f0eb3-d86b-41c6-906b-33bbce4c006e.

For more information or to schedule a one-on-one meeting with management, please visit the conference website at: https://hcwevents.com/annualconference/.

https://www.geovax.com/news/geovax-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.